Track topics on Twitter Track topics that are important to you
Selvita delivers comprehensive solutions to customers from the pharmaceutical and biotechnology industry targeted at speedy and cost-effective introduction of efficacious and safe drugs to the market.
The areas of our activity include:
Selvita is also the majority shareholder of BioCentrum (www.biocentrum.com.pl), which provides preclinical ADMET services, and biopharmaceutical development services. Selvita Group laboratories have the General Pharmaceutical Inspectorate accreditation and Good Laboratory Practice (GLP) certification.
Selvita develops its own innovative drugs, which originate from research at Polish universities and later commercializes them with partners from the pharmaceutical industry. Selvita is involved in several research projects at the pre-clinical stage. Our current projects are in the area of oncology and central nervous system.
We employ over 160 top-class professionals from the area of medicine, chemistry, pharmacy, molecular biology, biotechnology and informatics, and almost 40% of Selvita employees hold a PhD degree in the field of biomedical research. Many of our experts have several years of experience in the biotechnology and pharmaceutical companies in the U.S., Canada, UK, Germany and Poland, and publications in the best scientific journals such as: Nature Biotechnology, Science, and the Journal of Medicinal Chemistry. We work with leading universities and research centers from Poland, Europe and United States.
In our work we adhere to the highest ethical standards, both in dealing with the environment and within the company. Our goal is to develop solutions that contribute to the extension and improvement of the quality of life. In doing so, Selvita is guided by the respect for human life at it's every stage, and does not conduct research which violates human dignity.
Park Life Science
ul. Bobrzyńskiego 14,
Phone: +48 12 297 47 00
Fax: +48 12 297 47 01
Poland’s leading biopharma company Selvita today announced the appointment of Steffen Heeger to the…
Edison Investment Research - Pharmaceutical & healthcare - Selvita: Selvita’s FY17 revenues were PLN105.9m, up 59% y-o-y, with adjusted operating profit rising from PLN4.7m to PLN13.2m. This ref...
Polish biotech firm Selvita pleased investors with its announcement of a major share 2.2 million placement,…
Poland’s leading biotech firm Selvita has confirmed its intention to conduct a secondary public offering.
Despite announcing that positive trial results had been published on its lead cancer drug candidate,…
Krakow, Poland, April 06, 2018 / B3C newswire / -- Selvita (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, will publish the m...
Selvita delivers comprehensive solutions to customers from the pharmaceutical and biotechnology industry targeted at speedy and cost-effective introduction of efficacious and safe drugs to the marke...
We have published hundreds of Selvita S.A. news stories on BioPortfolio along with dozens of Selvita S.A. Clinical Trials and PubMed Articles about Selvita S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Selvita S.A. Companies in our database. You can also find out about relevant Selvita S.A. Drugs and Medications on this site too.
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...